Significant collaborations and licensing agreements are reshaping therapeutic landscapes, highlighted by Novartis’ $200 million collaboration with Arrowhead Pharmaceuticals to develop RNAi therapies targeting Parkinson’s disease and Radiance Biopharma’s $1.165 billion deal for a bispecific nanobody ADC against solid tumors. These strategic moves underscore sustained industry commitment to cutting-edge modalities including siRNA therapeutics and nanobody platforms, accelerating advancement of novel treatments for serious diseases.